Status:
COMPLETED
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
Lead Sponsor:
GlaxoSmithKline
Conditions:
Dyslipidaemias
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol"...
Detailed Description
A multi-center, three-staged, randomized, parallel group, sequential, double-blind, fenofibrate-and placebo-controlled dose-response evaluation of the safety, tolerability, and effects on plasma HDLc ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- High-density lipoprotein cholesterol less than or equal to 45 mg/dL.
- Triglycerides greater than or equal to 120 mg/dL and less than or equal to 500 mg/dL.
- Women must be surgically sterile or postmenopausal.
- Exclusion criteria:
- Heart disease
- Diabetes
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00169559
Start Date
November 1 2003
End Date
April 1 2005
Last Update
October 22 2012
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35243
2
GSK Investigational Site
Phoenix, Arizona, United States, 85014
3
GSK Investigational Site
Phoenix, Arizona, United States, 85050
4
GSK Investigational Site
Scottsdale, Arizona, United States, 85251